ΑD				

Award Number: DAMD17-03-1-0259

TITLE: The Role of Cyclin E and Its Lower Molecular Forms in the Oncogenesis of Ovarian Cancer and Its Predictive Value in Patients with Early Stage Ovarian Tumor

PRINCIPAL INVESTIGATOR: Khandan Keyomarsi, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas

MD Anderson Cancer Center

Houston, TX 77030

REPORT DATE: April 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE		2. REPORT TYPE		-	ATES COVERED	
01-04-2006		Annual			pr 2005 – 31 Mar 2006	
4. TITLE AND SUBTIT	LE			5a. (CONTRACT NUMBER	
		olecular Forms in th		· an ian	GRANT NUMBER	
Cancer and Its Pre	edictive Value in Pa	tients with Early Sta	ige Ovarian Tumor		MD17-03-1-0259	
				5c. l	PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d.	PROJECT NUMBER	
Khandan Keyomarsi, Ph.D.				5e. `	TASK NUMBER	
				5f. V	WORK UNIT NUMBER	
7. PERFORMING OR	SANIZATION NAME(S)	AND ADDRESS(ES)		8. P	ERFORMING ORGANIZATION REPORT	
				N	UMBER	
The University of						
MD Anderson Car	ncer Center					
Houston, TX 7703	30					
9. SPONSORING / MO	NITORING AGENCY N	IAME(S) AND ADDRESS	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)	
	I Research and Ma		J(_J)		o. oo.,(o,	
Fort Detrick, Mary						
Tore Bouron, mary	Idild 21702 0012			11 :	SPONSOR/MONITOR'S REPORT	
					NUMBER(S)	
				'	NOMBER(O)	
42 DISTRIBUTION /	VAILABILITY STATEN	ACNT.				
	ic Release; Distribu					
Approved for Fubi	ic Release, Distribu	illon Onlinnilea				
40 OLIDBI EMENITAD	13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white.					
		DTIC repreduction	مع بامعاط من مط النبير مر	d white		
		L DTIC reproduction	ns will be in black an	d white.		
Original contains		L DTIC reproduction	ns will be in black an	d white.		
Original contains	colored plates: AL	•				
Original contains 14. ABSTRACT The deregulation of	colored plates: AL	oints, with loss of re	gulation at the G1/S	transition, has	s been shown to play an important	
Original contains 14. ABSTRACT The deregulation of role in the transformation of the t	colored plates: AL	oints, with loss of reant phenotype. Our	gulation at the G1/S studies have focuse	transition, has	which appears in late G1 and	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction	of cell cycle checkp mation to a maligna on point .We hypoth	oints, with loss of reant phenotype. Our nesize that alteration	gulation at the G1/S studies have focuse s of cyclin E in ovar	transition, has ed on cyclin E, ian cancer cel	which appears in late G1 and Is contributes to the oncogenesis of	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction	of cell cycle checkp mation to a maligna on point .We hypoth	oints, with loss of reant phenotype. Our nesize that alteration	gulation at the G1/S studies have focuse s of cyclin E in ovar	transition, has ed on cyclin E, ian cancer cel	which appears in late G1 and	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors an	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact	oints, with loss of reant phenotype. Our nesize that alteration so outcome in patien	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca	transition, has ed on cyclin E, ian cancer cel ncer. In this p	which appears in late G1 and ls contributes to the oncogenesis of proposal we will i) develop a	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive ovarians.	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact varian cell line mode	oints, with loss of reant phenotype. Our nesize that alteration so outcome in patien left for characterization	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive oversign E and its turns.	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact arian cell line mode mor specific LMW for	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien of the characterizations in the developroms in the developromes.	gulation at the G1/S studies have focuse as of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant p	transition, has d on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic value.	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact rarian cell line mode mor specific LMW for ue of the hyperactive	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien of the characterization orms in the developme forms of cyclin E in	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III can of the role of cycliment of malignant plan patients with Stagen	transition, has d on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic valuation biochemical signif	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact arian cell line mode mor specific LMW for ue of the hyperactive cance of the LMW	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patiened for characterization orms in the developme forms of cyclin E informs of cyclin	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic valuation biochemical signifus needed information	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact varian cell line mode mor specific LMW for ue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patiened for characterization orms in the developme forms of cyclin E informs of cyclin	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic valuation biochemical signif	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact varian cell line mode mor specific LMW for ue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patiened for characterization orms in the developme forms of cyclin E informs of cyclin	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic valuation biochemical signifus needed information	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact varian cell line mode mor specific LMW for ue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patiened for characterization orms in the developme forms of cyclin E informs of cyclin	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive overgelin E and its turn the prognostic valuation biochemical signifus needed information targeted therapies	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact varian cell line mode mor specific LMW foue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patiened for characterization orms in the developme forms of cyclin E informs of cyclin	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive overgelin E and its turn the prognostic valuation biochemical signifus needed information targeted therapies	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact varian cell line mode mor specific LMW foue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien of characterization orms in the development of cyclin E informs of cyclin E in lar biology of ovaria	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive overgelin E and its turn the prognostic valuation biochemical signifus needed information targeted therapies	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact varian cell line mode mor specific LMW foue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien of characterization orms in the development of cyclin E informs of cyclin E in lar biology of ovaria	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic valuation biochemical signiff needed information targeted therapies 15. SUBJECT TERMS Ovarian cancer, cyclin and contains the contai	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact arian cell line mode mor specific LMW for ue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien of characterization orms in the development of cyclin E informs of cyclin E in lar biology of ovaria	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results fron	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much venues for the development of	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive overgelin E and its turn the prognostic valuation biochemical signifus needed information targeted therapies	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact arian cell line mode mor specific LMW for ue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien of characterization orms in the development of cyclin E informs of cyclin E in lar biology of ovaria	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this part E in ovarian the I-III ovarian the results from ay open new a	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much venues for the development of	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic valuation biochemical signiff needed information targeted therapies 15. SUBJECT TERMS Ovarian cancer, cyclin and contains the contai	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact arian cell line mode mor specific LMW fo ue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien or characterization orms in the development of cyclin E in forms of cyclin E in a lar biology of ovariant, predictive marker	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this p n E in ovarian nenotype in vit e I-III ovarian he results from ay open new a	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much venues for the development of	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive over cyclin E and its turn the prognostic valuation biochemical signiff needed information targeted therapies 15. SUBJECT TERMS Ovarian cancer, cyclin and contains the contai	of cell cycle checkp mation to a malignation point. We hypothe disconnected in point with the modern specific LMW for the hyperactive cance of the LMW is about the molecular control of the control of t	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien of characterization orms in the development of cyclin E informs of cyclin E in lar biology of ovaria	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this part E in ovarian the I-III ovarian the results from ay open new a	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much venues for the development of 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area	
Original contains 14. ABSTRACT The deregulation of role in the transfor flanks the restriction ovarian tumors and comprehensive overgin E and its turn the prognostic valuation biochemical signiful needed information targeted therapies 15. SUBJECT TERMS Ovarian cancer, contains the contains of the co	of cell cycle checkp mation to a maligna on point .We hypoth d negatively impact arian cell line mode mor specific LMW fo ue of the hyperactive icance of the LMW n about the molecu	oints, with loss of reant phenotype. Our nesize that alteration is outcome in patien or characterization orms in the development of cyclin E in forms of cyclin E in a lar biology of ovariant, predictive marker	gulation at the G1/S studies have focuse is of cyclin E in ovar ts with Stage I-III ca n of the role of cycli ment of malignant pl n patients with Stag tumor specimens. T	transition, has ed on cyclin E, ian cancer cel ncer. In this part E in ovarian the I-III ovarian the results from ay open new a	which appears in late G1 and Is contributes to the oncogenesis of proposal we will i) develop a cancer, ii) delineate the role of tro and in nude mice. iii) establish cancer and iv) examine the nour studies will provide much venues for the development of 19a. NAME OF RESPONSIBLE PERSON USAMRMC	

TABLE OF CONTENTS

Introduction	pages 4
Body/Results	pages 5
Discussion	page 8
Conclusion	nage 9

Introduction:

The overall purpose of this 3 year study is to test the hypothesis that alterations of cyclin E in ovarian cancer cells contributes to the oncogenesis of ovarian tumors and negatively impacts outcome in patients with Stage I-III ovarian cancer.

Over expression of the cyclin E protein has been linked to shortening of G1 (ohtsubo 1993), decreased requirement for growth factors (ohtsubo 1993), enhanced proliferation (bedrosian 2004), induction of chromosomal instability (Spruck, Akli 2004) and polyploidy (Lengauer lab FBW7/HCT ppr). These processes are felt to contribute towards the oncogenic potential pf cyclin E. The clinical relevance of cyclin E over expression is seen in multiple malignancies where cyclin E over expression is linked to poorer outcomes (Bani-Hani, Tissier, Ferreri, Rosen 2006, Farley, Keyomarsi NEJM, Porter 1997, Fukuse, Jang 1999, Mishina), most notably in breast (Keyomarsi NEJM, Porter 1997) and ovarian cancer (Rosen 2006, Farley).

Although the prognostic role of cycin E is well established, and cyclin E has been shown to mediate resistance to anti-estrogens, there is limited information as to its role as a predictor of response to chemotherapy. We have previously reported that over expression of LMW cyclin E in an *in vitro* ovarian cancer model provides these cells with a proliferative advantage and resistance to inhibition by p21 and 27. LMW cyclin E overexpression in this model system also increased sensitivity to cisplatin treatment. We therefore hypothesized that cyclin E over expression, by abrogating the G1 checkpoint and increasing the proliferative fraction would make tumor cells more susceptible to S phase targeted therapies such as cisplatin. In addition, since the biologic activity of cyclin E is effected through is associated kinase activity, we further hypothesized that cyclin E over expression and thus, enhanced kinase activity, would also predict

for response to platinum based therapy. We tested this hypothesis in a cohort of 111 patients with advanced ovarian carcinoma who underwent platinum based chemotherapy at the University of Texas, M.D.Anderson Cancer Center.


Results

In the third year of the proposed grant we have completed the last aim/task of this grant application and will be submitting our work for publication.

Task 5: Collection and processing of ovarian tumor tissue







Samples	Week 1 (% of ctrl)	Week 2 (% of ctrl)	Mean	Standard deviation
Control	100	100	100	n/a
1	35	52	43.5	12
2	28	33	30.5	3.5
3	24	27	25.5	2.1
4	10	9	9.5	0.7
5	54	40	47	9.9
6	96	94	95	1.4
7	19	8	13.5	7.8
8	12	13	12.5	0.7
9	31	35	33	2.8
10	23	27	25	2.8

Determination of

cyclin E associated

kinase activity

Sufficient sample was available from 108

patients for cyclin E

associated kinase

evaluation. Cyclin E

immunoprecipitates

from each tumor

sample were assessed for cyclin E associated kinase activity using Histone H1 as substrate.


Relative kinase activity for each sample was calculated as a percent of reference control sample.

In order to ensure reproducibility of the assay, 11 samples (10%) were repeated at least twice.

These samples were repeated on separate on separate days at least 1 week apart. The results of 10 of these samples are shown in Figure 1. Sample means and standard deviation were calculated

for each replicate sample and the co-efficient of variation was computed. The average coefficient of variation was 9.9% indicating high reproducibility.

Association between cyclin E expression and its associated kinase activity We next examined the correlation between cyclin E expression level and its associated kinase activity in the 108 patients for whom both data points had been obtained. Cyclin E kinase assays were performed using Histone H1 as substrate. We found that cyclin E protein level in the tumor samples did not correlate with the level of cyclin E associated kinase activity (Figure 2) This result demonstrates the complexity of kinase activity which depends not only on the protein level of cyclin E, but also on the levels of its kinase binding partner, cdk2, and additionally on the expression of the natural inhibitors, p21 and p27. Since cyclin E activity did not appear to be linked to cyclin E protein levels, we next sought to assess the importance of each of these two parameters of cyclin E over expression on response to treatment to chemotherapy.



Response to chemotherapy

Clinical data on 110 patients was available to determine response to chemotherapy. Response to therapy was defined as per the GOG criteria. Patients who progressed on chemotherapy or who relapsed within 6 months of completing therapy were deemed to be non-responders. All other patients were categorized as responders to chemotherapy. Using this criteria, 48 patients were identified as non-responders and 63 were responders. In a univariate analysis, predictors of response to chemotherapy included optimal surgery, cyclin E and p27 expression levels (Table 1). All patients who responded had received optimal debulking. A significantly lower incidence of response was seen in patients who expressed high levels of cyclin E and among those who expressed high levels of p27 protein. Cyclin E associated kinase activity was not predictive of chemotherapy response.

We next attempted to perform multivariate logistic analysis of treatment response using the factors with univariate significance (optimal vs suboptimal surgery, cyclin E expression and p27 expression). Since all responding patients were limited to the optimally debulked group, we planned to perform the analysis in only the subset of patients with optimal surgery. However, only one factor was significant in this subgroup, cyclin E expression level, therefore no further analysis was possible.

Table 1

Variable	p-value
Age	0.058

Stage (III vs IV)	0.076
Histology (serous vs other)	0.763
Surgery (optimal vs	0.014
suboptimal)	
Cyclin E expression (high	0.017
vs low)	
Cyclin E associated kinase	0.288
activity	
p27 expression (high vs	0.046
low)	

DISCUSSION

Over expression of cyclin E has been reported in many human cancers (REF) and in many studies is linked to poor prognosis (REF). Less well known is the role of cyclin E as a marker of response to chemotherapy. Over expression of cyclin E is thought to result in enhanced activity of the cyclin E-cdk2 complex and a more efficient transition into S-phase. Therefore, cyclin E overexpressing cells would be expected to be more susceptible to agents that target S-phase such as cisplatin and carboplatin. In this study, we test this hypothesis and find that although cyclin E levels predict for response to chemotherapy, cyclin E associated kinase activity does not. Furthermore we find that it is low rather than high levels of cyclin E that predict for a population most likely to respond to platinum based therapy. These data therefore suggest that high levels

of cyclin E mediate alterations independent of its kinase regulatory function that leads to resistance.

Several lines of evidence suggest that cyclin E may have important biological roles that are independent of its ability to bind and activate cdk2. Whereas cdk2 has been shown to be dispensable for tumor formation in p27 null animals, cyclin E deficient cells are relatively resistant to oncogenic transformation (Geng, Cell 2003). More direct evidence comes from recent data that cyclin E has a centrosomal localization signal that is independent of its kinase function (Matsumoto, Science 2004). Results fromour study now provide translational support for the kinase dependent and kinase independent activities of cyclin E.

As agents targeting cyclin dependent kinases undergo clinical trials, the results from our study highlight that cyclin levels may not be an appropriate surrogate for cyclin associated kinase activity. For instance, cyclin E activity is dependent on multiple factors in addition to the level of cyclin E expression, including expression of cdk2, p21 and p27. It is the sum of these components that determines the ultimate activity of the cyclin E-cdk2 complex which mediates the transition across the restriction point into S-phase. Our data therefore suggests that therapies that target the cyclin dependent kinase activity may need to select patients on the basis of kinase function rather than expression of the target protein.

Conclusions

As presented in detail in this report-we have addressed task 5 of the grant application in the last 12 months.